anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Epithelial ingrowth is one of the most significant complications of Laser in Situ Keratomileusis (LASIK) refractive surgery. We present the case of a 72-year-old male with a history of myopic LASIK (1999), who underwent cataract surgery and a second thin LASIK sub-Bowman flap to correct refractive error. Then, three months after pars plana vitrectomy for an epiretinal membrane, the patient complained of progressive vision loss. A diffuse haze of the corneal stroma that did not exist before surgery was observed. As the main suspicion was epithelial ingrowth, the flap was lifted and meticulous de-epithelialization of the stromal bed was performed. Mitomycin C 0.02% was applied, the flap was sutured with 10-0 Nylon, and a bandage contact lens was placed. The epithelialization of the interface after vitrectomy in a patient with LASIK could occur even when it is a rare complication and without obvious flap traumatism.
The invention discloses radionuclide marked denomab, a precursor compound, a preparation method and application thereof, and belongs to the technical field of nuclear medicine. The precursor compound has a structure shown in a formula I-1, a formula I-2 or a formula I-3. The present invention also provides radionuclide-labeled compounds of the above precursor compounds. The preparation method of the precursor compound comprises the following steps: dinodizumabAnd reacting with p-SCN-Bn-DOTA, p-SCN-Bn-NOTA or p-SCN-Bn-DFO to obtain the compound shown in formula I-1, formula I-2 or formula I-3. The preparation method of the radionuclide marked denomab comprises the following steps: and (3) reacting the precursor compound with a radionuclide salt solution to obtain the radionuclide-marked denomab. The radionuclide marked denomab has simple marking method, proper reaction time and higher marking yield, and can realize the imaging and treatment effects on RANKL/RANK signal channel diseases such as metastatic bone tumor, bone giant cell tumor and multiple myeloma.
The study design is a two-arm, parallel group, assessor-blinded, randomised controlled trial. The hypothesis is that technology-enabled anticipatory guidance and peer support is more effective than conventional oral health education in enhancing parental efficacy, establishing proper childcare practices (dietary, feeding and toothbrushing), and preventing ECC. Up to 600 mother-child dyads will be recruited and randomly assigned to receive conventional oral health education (control), and technology-enabled anticipatory guidance and peer support (intervention), respectively. For the intervention arm, anticipatory guidance and peer support will be delivered through 4 unique online sessions for mothers, when each child turns 3, 6, 12, and 18 months, to match the developmental milestones and parental needs for childcare support. Outcomes will be assessed through a questionnaire and food diary (at 12, 24 and 36 months of child's age) and a dental examination for the child (at 24 and 36 months of age).

The effectiveness of the intervention will be evaluated using psychological outcomes (parental efficacy), behavioral outcomes (dietary, feeding and oral hygiene practices), and clinical outcomes (oral hygiene and ECC), and quality of life outcomes. Process evaluation and cost-effectiveness analysis will be included. Data will be analyzed on an intention-to-treat basis, including with the last observation carried forward method. Descriptive statistics on socio-demographic backgrounds, parental efficacy, childcare practices, child's oral health status, and oral health related quality of life will be reported. Chi-square test and two-sample t-test, or their non-parametric equivalents, will be used as appropriate to compare proportions and means between the control and intervention groups. Effect sizes and number needed to be treated will be presented to provide an estimate of the number of parents needed to be intervened in order to avoid one child with new dental caries. Multivariable analyses will be performed to evaluate the effectiveness of the intervention.
Waldenstrom macroglobulinaemia (WM) is a low grade nonHodgkin lymphoma characterised by bone marrow infiltration and the presence of an abnormal protein in the blood (IgM paraprotein. Most patients require treatment at presentation but there is no agreed standard of first line therapy. Current treatment is unsatisfactory with responses often incomplete and slow to attain, while recurrence is inevitable.

The aim of this study is to find out whether a new combination of Bortezomib (Velcade®), Cyclophosphamide and Rituximab (MabThera), is well tolerated and effective for patients with WM. R2W is a randomised, noncomparative, phase II trial of subcutaneous bortezomib, cyclophosphamide, rituximab (BCR, experimental arm) versus fludarabine, cyclophosphamide, rituximab (FCR, control arm) for initial therapy of WM. This is a two stage trial where six patients will be treated initially with BCR to assess tolerability. If BCR is considered tolerable, a further 50 patients will be randomised between BCR and FCR (2:1) in the second stage of the trial. Patients will receive 3 cycles of treatment and then be reassessed. Those with evidence of progression will stop trial treatment. All other patients will continue with a further 3 cycles (to a total of 6) unless there is a clear clinical contraindication to further treatment.
The present invention discloses externally used paste for treating burns and scalds. Locust tree bark, yellow beeswax, sanguisorba roots and borneol are put in refined lard and are decocted and processed. After the mixture is filtered and cooled, paste medicine is obtained. The present invention provides moist externally used paste, and the immediate pain alleviation is realized after use. The paste has the advantage of convenient use, and has no scar and no skin graft by operations after treatment. The paste can be used for treating various burns and scalds, and the paste also has good curative effect on frostbite.
INTRODUCTION: Heterotopic ossification (HO), or ectopic bone formation in soft tissue, is a not so rare and poorly understood debilitating sequela of burn injury. Individuals developing HO following burn injuries to their hands often experience reductions in mobility, significant contractures, and joint pain. This study identifies demographic characteristics of individuals who develop HO and compares their physical and psychosocial outcomes to the general burn population.
METHODS: Participant demographics, injury characteristics, and PROMIS-29 scores across three time points (discharge, six- and 12- months after injury) were extracted from the Burn Model System National Longitudinal Database representing participants from 2015-2022. Mixed-effects linear regression models were used to compare PROMIS scores across all three longitudinal measurements. Models were adjusted for age, sex, race/ethnicity, HO status, and burn size.
RESULTS: Of the 861 participants with data concerning HO, 33 were diagnosed with HO (3.8% of participants). Most participants with HO were male (n = 24, 73%) and had an average age of 40 + /- 13 years. Participants with HO had significantly larger burn size (49 +/-23% Total Body Surface Area (TBSA)) than those without HO (16 +/-17%). Participants with HO reported significantly worse physical function, depression, pain interference and social integration scores than those without HO. After adjusting for covariables, participants with HO continued to report statistically significantly worse physical function than those without HO. Although physical functioning was consistently lower, the two populations did not differ significantly among psychosocial outcome measures.
CONCLUSIONS: While HO can result in physical limitations, the translation to psychosocial impairments was not evident. Targeted treatment of HO with the goal of maximizing physical function should be a focus of their rehabilitation.
LEVEL OF EVIDENCE: 2b TYPE OF STUDY: Symptom Prevalence Study.
The present invention relates to a solvent used for dissolving penicillin for injection. The solvent uses water for injection or physiological saline as a resolvent and uses a water solution or saline solution of lidocaine as a penicillin solvent. The concentration of lidocaine in the solvent is from 0.10 to 0.40%, and the optimum concentration is from 0.15 to 0.25%. The solvent almost has no influence for the titer of penicillin. Experiments show that after injection, patients can better absorb the penicillin, and the probability that patients who have tubercle occur is less than 0.2%. The solvent has the good function of reducing pain. When the solvent is used for an allergy skin test, the occurrence of false positive results can be greatly reduced.
PURPOSE:To obtain the hydraulic matter which curse rapidly at about neutral pH and has excellent bioaffinity by constituting the matter of a powder agent essentially consisting of a mixture obtd. by mixing tertiary calcium phosphate and primary calcium phosphate so as to attain 1.400 to 1.498 Ca/P molar ratio and a liquid agent. CONSTITUTION:The tertiary calcium phosphate of the hydraulic calcium phosphate cement consisting of the powder agent essentially consisting of the mixture obtd. by mixing tertiary calcium phosphate and primary calcium phosphate so as to attain 1.400 to 1.498 Ca/P molar ratio and the liquid agent is made of a mixture composed of alpha type tertiary calcium phosphate and beta type tertiary calcium phosphate. This hydraulic calcium phosphate cement is formed by further incorporating the alpha type tertiary calcium phosphate into the beta type tertiary calcium phosphate and the primary calcium phosphate as the powder agent and, therefore, the cement maintains the strength without being deteriorated over a long period of time and can be cured within practicable time at the pH of the neutral region. Further, the cement has the excellent bioaffinity.
The sensitization following infection with mycobacteria occurs primarily in the regional lymph nodes. Small lymphocytes (T lymphocytes) proliferate in response to the antigenic stimulus to give rise to specifically sensitized lymphocytes. After 3-8 weeks, these lymphocytes enter the blood stream and circulate for years. (7) Subsequent restimulation of these sensitized lymphocytes with the same or a similar antigen, such as the intradermal injection of TUBERSOL, evokes a local reaction mediated by these cells. (8)

Characteristically, delayed hypersentitivity reactions to tuberculin begin at 5 to 6 hours, are maximal at 48 to 72 hours and subside over a period of days. The resultant immune response consists of induration due to cell infiltration and occasionally vesiculation and necrosis. Clinically, a delayed hypersensitivity reaction to tuberculin is a manifestation of previous infection with M tuberculosis or a variety of non-tuberculosis bacteria. In most cases sensitization is induced by natural mycobacterial infection or by vaccination with BCG Vaccine.
Tractography has become a widely available tool for the planning of neurosurgical operations as well as for neuroscientific research. The absence of patient interaction makes it easily applicable. However, it leaves uncertainty about the functional relevance of the identified bundles. We retrospectively analyzed the correlation of white matter markers with their clinical function in 24 right-handed patients who underwent first surgery for high-grade glioma. Morphological affection of the corticospinal tract (CST) and grade of paresis were assessed before surgery. Tractography was performed manually with MRTrix3 and automatically with TractSeg. Median and mean fractional anisotropy (FA) from manual tractography showed a significant correlation with CST affection (p = 0.008) and paresis (p = 0.015, p = 0.026). CST affection correlated further most with energy, and surface-volume ratio (p = 0.014) from radiomic analysis. Paresis correlated most with maximum 2D column diameter (p = 0.005), minor axis length (p = 0.006), and kurtosis (p = 0.008) from radiomic analysis. Streamline count yielded no significant correlations. In conclusion, mean or median FA can be used for the assessment of CST integrity in high-grade glioma. Also, several radiomic parameters are suited to describe tract integrity and may be used to quantitatively analyze white matter in the future.
The invention discloses cream mainly for treating traumatic injuries and a preparation method. The cream is prepared from, by weight, 3-6 parts of grewia eriocarpa Juss.[G.lantsangensis Hu], 4-9 parts of gaultheriayunnanensis (Franch.) Rehd.G.CrenulataKurzi;VacciniumyunnanenseFranch.L, 6-15 parts of radix achyranthis bidentatae, 8-16 parts of pericarpium citri reticulatae viride, 4-9 parts of tinospora sinensis (Lour.) Merr., 3-6 parts of roots of Korean raspberries and a proper amount of egg white. The cream has the advantages that the cream is prepared from multiple types of traditional Chinese medicine, matching is reasonable, the curative effect on traumatic injuries is good, both symptoms and root causes of disease can be treated, the curative effect is high in speed, no toxic or side effect exists, and relapse is avoided after recovery. The cream has the pharmacologic actions of invigorating the circulation of blood, eliminating stagnant blood, resisting to inflammation and relieving pain and is suitable for treating traumatic injuries. The medical source is easy to obtain, the medical material cost is low, and burden of patients can be relieved.
PURPOSE: To obtain a liposome type dihydropyridine preparation capable of parenteral administration. CONSTITUTION: This preparation is a stable pharmaceutical preparation based on liposome that contains an active compd. and a phospholipid in a ratio of 1:20 to 1:100, has 40-200 nm average diameter and has a phospholipid membrane, not contg. an org. solvent. capable of parenteral administration and having pH 4.5-6.5 after restoration.
BACKGROUND & AIMS: Although upper gastrointestinal endoscopy (EGD) remains the gold standard for detecting varices in cirrhosis, the Baveno VI criteria proposed a combination of transient elastography and platelet count that could rule out high-risk varices, therefore sparing the need for an endoscopy, with significant potential cost savings. We performed a cost-effectiveness analysis of the Baveno VI criteria compared with EGD in the diagnosis of high-risk varices in cirrhosis.
METHODS: We built an analytical decision model to estimate the cost and benefits of using the Baveno VI criteria compared with EGD in patients with Child-Pugh A cirrhosis. The analysis was performed from the UK National Health Service perspective, over 1, 5, and 20 years. A Markov model was populated with data from published evidence. Outcomes were measured in terms of quality-adjusted life years (QALYs) and avoided deaths. The analyses were repeated for Canada and Spain, using relevant cost inputs.
RESULTS: The Baveno VI criteria were cost effective compared with endoscopy in all analyses. For 1000 patients, they produced 0.16 additional QALYs at an incremental cost of £326 ($443.41) over 5 years, resulting in an incremental cost of £2081 ($2830) per additional QALY gained. The incremental net monetary benefit of Baveno VI compared with EGD was £2808 ($3819) over 5 years per patient. Baveno VI criteria also were cost effective in Canada and Spain. Deterministic and probabilistic sensitivity analysis supported these findings.
CONCLUSIONS: The findings demonstrate that the Baveno VI criteria are cost effective, suggesting that they should be considered for widespread implementation on the basis of safety, appropriateness, and economic grounds.
Patients with infected diabetic foot were grouped according to the Wagner system for classifying foot lesions. All patients presented Wagner Grade 3 classification, with osteomyelitis in one or more toes. The study included only patients who had circulatory viability.

For PDT treatment the fistula and/or ulcer was used as a gateway to the bone. The treated area (bones and fingers) was irrigated with a solution of phenothiazinium salts. After that, light irradiation was performed with optical fibers or led device above the wound. PDT treatment always in outpatients, once or twice a week.
Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
The application provides a method and equipment related to drug list management. Drug associations between one or more diagnoses and one or more corresponding drugs recorded in the medical record are determined via the assessment model. The assessment model is trained via a machine learning algorithm. Multiple drug categories are integrated into the medical record based on the drug association. The medicament comprises one or both of a first medicament and a second medicament. The drug categories include interpreted categories related to a first drug having a higher drug association and unexplained categories related to a second drug having a lower drug association. A medication list interface is provided that presents medical records having a plurality of medication categories. Thus, the medication history will be structured, grouped, and visually encoded to provide an intuitive medication inventory.
The present invention is a cold solution for reducing adipose tissue or fat. Delivering the cold solution to a region of lipid-rich tissue induces the natural cell death of adipocytes and thereby reduces the tissue. Following cell death, localized panniculitis or inflammation of the tissue leads to further reduction as adipocytes are removed as a result of phagocytosis. The cold solution does not have ice particles. One or more additives, including salt, sugar, thickeners, freezing point depressants, surfactants, and excipients can be added to the cold solution to facilitate/enhance fat reduction. Fat reduction by cold solution injection can be used to improve one's appearance or to treat a weight-related disorder, such as obesity.
The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.
This study aims to evaluate various methods of measuring pain relief in osteoarthritis (OA) of the knee. The duration of the study will be up to 5 weeks. Eligible subjects will have chronic OA of the knee. After meeting initial entry criteria and prior to randomization, there will be a 1 week wash-out from existing therapy. Subjects will then be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have a week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, nor will they be allowed to use topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication (as needed up to 2 g/day)but subjects will be told not to take acetaminophen at least 12 hours before study visits. Seventy (70) subjects will be randomized to ensure that 60 subjects complete both treatment arms.
Pulmonary vein encirclement is achieved using contiguous applications of very high power and short duration (90 W over 4 seconds). The inter-lesion distance is set at 3-4mm for the roofs and anterior segments, and 5-6mm for other segments. If the esophageal temperature rises \> 38 for segments near the esophagus, encirclement will be applied at 25 W for 15 seconds.
Matching placebo for YN001 is 5% dextrose injection. Subjects will be administered 250 to 500mL of 5% dextrose injection up to 120 min (which allows a +/-5 min infusion window) intravenous infusion.
Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
BACKGROUND: Leukocyte immunoglobulin-like receptor B4 (LILRB4) plays a significant role in regulating immune responses. LILRB4 in microglia might influence the infiltration of peripheral T cells. However, whether and how LILRB4 expression aggravates brain damage after acute ischemic stroke remains unclear. This study investigates the role of LILRB4 in modulating the immune response and its potential protective effects against ischemic brain injury in mice.
METHODS AND RESULTS: Microglia-specific LILRB4 conditional knockout (LILRB4-KO) and overexpression transgenic (LILRB4-TG) mice were constructed by a Cre-loxP system. Then, they were used to investigate the role of LILRB4 after ischemic stroke using a transient middle cerebral artery occlusion (tMCAO) mouse model. Spatial transcriptomics analysis revealed increased LILRB4 expression in the ischemic hemisphere. Single-cell RNA sequencing (scRNA-seq) identified microglia-cluster3, an ischemia-associated microglia subcluster with elevated LILRB4 expression in the ischemic brain. Flow cytometry and immunofluorescence staining showed increased CD8+ T cell infiltration into the brain in LILRB4-KO-tMCAO mice. Behavioral tests, cortical perfusion maps, and infarct size measurements indicated that LILRB4-KO-tMCAO mice had more severe functional deficits and larger infarct sizes compared to Control-tMCAO and LILRB4-TG-tMCAO mice. T cell migration assays demonstrated that LILRB4-KD microglia promoted CD8+ T cell recruitment and activation in vitro, which was mitigated by CCL2 inhibition and recombinant arginase-1 addition. The scRNA-seq and spatial transcriptomics identified CCL2 was predominantly secreted from activated microglia/macrophage and increased CCL2 expression in LILRB4-KD microglia, suggesting a chemokine-mediated mechanism of LILRB4.
CONCLUSION: LILRB4 in microglia plays a crucial role in modulating the post-stroke immune response by regulating CD8+ T cell infiltration and activation. Knockout of LILRB4 exacerbates ischemic brain injury by promoting CD8+ T cell recruitment. Overexpression of LILRB4, conversely, offers neuroprotection. These findings highlight the therapeutic potential of targeting LILRB4 and its downstream pathways to mitigate immune-mediated damage in ischemic stroke.